GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theravance Biopharma Inc (NAS:TBPH) » Definitions » Shiller PE Ratio

Theravance Biopharma (Theravance Biopharma) Shiller PE Ratio : (As of May. 15, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Theravance Biopharma Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Theravance Biopharma Shiller PE Ratio Historical Data

The historical data trend for Theravance Biopharma's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theravance Biopharma Shiller PE Ratio Chart

Theravance Biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Theravance Biopharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Theravance Biopharma's Shiller PE Ratio

For the Biotechnology subindustry, Theravance Biopharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theravance Biopharma's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theravance Biopharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Theravance Biopharma's Shiller PE Ratio falls into.



Theravance Biopharma Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Theravance Biopharma's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Theravance Biopharma's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.17/129.4194*129.4194
=-0.170

Current CPI (Dec. 2023) = 129.4194.

Theravance Biopharma Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -1.860 99.695 -2.415
201406 -1.830 100.560 -2.355
201409 -1.720 100.428 -2.217
201412 -2.020 99.070 -2.639
201503 -1.290 99.621 -1.676
201506 -1.420 100.684 -1.825
201509 -1.400 100.392 -1.805
201512 -1.220 99.792 -1.582
201603 -1.100 100.470 -1.417
201606 -1.060 101.688 -1.349
201609 -0.730 101.861 -0.928
201612 -1.360 101.863 -1.728
201703 -1.270 102.862 -1.598
201706 -1.270 103.349 -1.590
201709 -1.270 104.136 -1.578
201712 -1.640 104.011 -2.041
201803 -1.220 105.290 -1.500
201806 -0.760 106.317 -0.925
201809 -1.100 106.507 -1.337
201812 -0.920 105.998 -1.123
201903 -1.320 107.251 -1.593
201906 -0.720 108.070 -0.862
201909 -1.050 108.329 -1.254
201912 -1.170 108.420 -1.397
202003 -1.400 108.902 -1.664
202006 -1.000 108.767 -1.190
202009 -1.160 109.815 -1.367
202012 -0.920 109.897 -1.083
202103 -1.240 111.754 -1.436
202106 -0.800 114.631 -0.903
202109 -0.480 115.734 -0.537
202112 -0.430 117.630 -0.473
202203 -0.340 121.301 -0.363
202206 -0.110 125.017 -0.114
202209 12.140 125.227 12.546
202212 -0.150 125.222 -0.155
202303 -0.350 127.348 -0.356
202306 -0.280 128.729 -0.282
202309 -0.170 129.860 -0.169
202312 -0.170 129.419 -0.170

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Theravance Biopharma  (NAS:TBPH) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Theravance Biopharma Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Theravance Biopharma's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Theravance Biopharma (Theravance Biopharma) Business Description

Traded in Other Exchanges
Address
Ugland House, South Church Street, George Town, PO Box 309, Grand Cayman, CYM, KY1-1104
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Executives
Rhonda Farnum officer: SVP, Comm & Medical Affairs 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Richard A Graham officer: SVP, Development 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Kelly James Connor director 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Susannah Gray director 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Brett A. Grimaud officer: SVP, Gen Counsel and Secretary 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Aziz Sawaf officer: SVP & Chief Financial Officer 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Rick E Winningham director, officer: Chief Executive Officer 901 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Andrew A. Hindman officer: SVP, Chief Financial Officer C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Eli Samaha 10 percent owner ONE WORLD TRADE CENTER, FLOOR 65, NEW YORK NY 10007
Wam Gp Llc 10 percent owner 222 BERKELEY STREET, 16TH FLOOR, BOSTON MA 02116
Andrew M Weiss 10 percent owner 222 BERKELEY STREET, 16TH FLOOR, BOSTON MA 02116
Weiss Asset Management Lp 10 percent owner 222 BERKELEY STREET, 16TH FLOOR, BOSTON MA 02116
Philip D Worboys officer: SVP, Translational Science 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Brett K Haumann officer: VP-Clinical Develop. 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Deepika Pakianathan director 160 BOVET ROAD, SUITE 408, C/O DELPHI VENTURES, SAN MATEO CA 94402

Theravance Biopharma (Theravance Biopharma) Headlines

From GuruFocus